These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 21128027)
1. Renal imaging in patients with renal impairment. Poff JA; Hecht EM; Ramchandani P Curr Urol Rep; 2011 Feb; 12(1):24-33. PubMed ID: 21128027 [TBL] [Abstract][Full Text] [Related]
2. Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk. Nicholas BA; Vricella GJ; Smith M; Passalacqua M; Gulani V; Ponsky LE Can J Urol; 2012 Feb; 19(1):6074-80. PubMed ID: 22316507 [TBL] [Abstract][Full Text] [Related]
7. Nephrogenic systemic fibrosis and management of high-risk patients. Altun E; Semelka RC; Cakit C Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360 [TBL] [Abstract][Full Text] [Related]
8. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Perazella MA Curr Drug Saf; 2008 Jan; 3(1):67-75. PubMed ID: 18690983 [TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Thomsen HS; Marckmann P; Logager VB Cancer Imaging; 2007 Sep; 7(1):130-7. PubMed ID: 17905680 [TBL] [Abstract][Full Text] [Related]
10. Safe use of iodinated and gadolinium-based contrast media in current practice in Japan: a questionnaire survey. Tsushima Y; Ishiguchi T; Murakami T; Hayashi H; Hayakawa K; Fukuda K; Korogi Y; Sugimoto H; Takehara Y; Narumi Y; Arai Y; Kuwatsuru R; Yoshimitsu K; Awai K; Kanematsu M; Takagi R Jpn J Radiol; 2016 Feb; 34(2):130-9. PubMed ID: 26662468 [TBL] [Abstract][Full Text] [Related]
11. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Neuwelt EA; Hamilton BE; Varallyay CG; Rooney WR; Edelman RD; Jacobs PM; Watnick SG Kidney Int; 2009 Mar; 75(5):465-74. PubMed ID: 18843256 [TBL] [Abstract][Full Text] [Related]
12. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. Bhave G; Lewis JB; Chang SS J Urol; 2008 Sep; 180(3):830-5; discussion 835. PubMed ID: 18635232 [TBL] [Abstract][Full Text] [Related]
13. Safety of Contrast Material Use in Children. Soares BP; Lequin MH; Huisman TAGM Magn Reson Imaging Clin N Am; 2017 Nov; 25(4):779-785. PubMed ID: 28964467 [TBL] [Abstract][Full Text] [Related]
16. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? Thomsen HS; Marckmann P; Logager VB Acta Radiol; 2007 Jul; 48(6):593-6. PubMed ID: 17611863 [No Abstract] [Full Text] [Related]
17. Intravenous Imaging Contrast Media Complications: The Basics That Every Clinician Needs to Know. Rose TA; Choi JW Am J Med; 2015 Sep; 128(9):943-9. PubMed ID: 25820169 [TBL] [Abstract][Full Text] [Related]
18. Gadolinium use in patients with kidney disease: a cause for concern. Perazella MA; Rodby RA Semin Dial; 2007; 20(3):179-85. PubMed ID: 17555477 [TBL] [Abstract][Full Text] [Related]
19. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Chrysochou C; Power A; Shurrab AE; Husain S; Moser S; Lay J; Salama AD; Kalra PA Clin J Am Soc Nephrol; 2010 Mar; 5(3):484-9. PubMed ID: 20093350 [TBL] [Abstract][Full Text] [Related]
20. GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review. Beam AS; Moore KG; Gillis SN; Ford KF; Gray T; Steinwinder AH; Graham A Radiol Technol; 2017 Jul; 88(6):583-589. PubMed ID: 28900045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]